Luis Souhami

Luis Souhami's AcademicInfluence.com Rankings

Luis Souhami

Physics

#7233

World Rank

#9251

Historical Rank

Biophysics

#309

World Rank

#321

Historical Rank

physics Degrees

Luis Souhami

Philosophy

#9064

World Rank

#12563

Historical Rank

Logic

#6061

World Rank

#7541

Historical Rank

philosophy Degrees

Download Badge

Physics
Philosophy

Luis Souhami's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biophysics University of California, San Francisco

Why Is Luis Souhami Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luis Souhami's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial (2004) (2254)
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. (2000) (2026)
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. (2000) (1365)
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. (2013) (954)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. (2006) (685)
Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. (1993) (621)
Radiotherapy and short-term androgen deprivation for localized prostate cancer. (2011) (495)
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. (2004) (490)
Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. (2002) (468)
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer (2017) (449)
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. (2003) (438)
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. (2014) (354)
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial (2018) (345)
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. (2005) (345)
Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). (1996) (261)
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. (2013) (259)
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma (2012) (236)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial (2019) (236)
Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. (2003) (226)
A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. (1991) (222)
The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. (2000) (213)
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer (2015) (206)
A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus (1991) (198)
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. (2005) (186)
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. (2005) (179)
Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. (1991) (178)
Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. (2013) (167)
Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). (2013) (142)
Radiosurgery with high energy photon beams: a comparison among techniques. (1989) (133)
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. (2018) (122)
Pre-treatment risk stratification of prostate cancer patients: A critical review. (2012) (118)
Controversies in prostate cancer radiotherapy: consensus development. (2001) (114)
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). (2015) (114)
Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. (2009) (107)
The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. (2004) (101)
The Management of Brain Metastases in Non-Small Cell Lung Cancer (2014) (97)
A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. (2012) (96)
The prediction of late rectal complications in patients treated with high dose-rate brachytherapy for carcinoma of the cervix. (1997) (91)
Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. (1993) (89)
Conformal Preoperative Endorectal Brachytherapy Treatment for Locally Advanced Rectal Cancer (2002) (89)
Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. (2004) (89)
Fractionated stereotactic radiation therapy for intracranial tumors (1991) (88)
Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. (2009) (88)
Rectal complications in patients with carcinoma of the cervix treated with concomitant cisplatin and external beam irradiation with high dose rate brachytherapy: a dosimetric analysis. (1994) (87)
Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance (2008) (85)
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. (2019) (83)
Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. (2002) (80)
Radiosurgery of cerebral arteriovenous malformations with the dynamic stereotactic irradiation. (1990) (79)
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. (2007) (76)
Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. (2014) (72)
Malignant lymphoma of the thyroid gland. (1980) (71)
Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. (2008) (69)
Stereotactic radiosurgery with whole brain radiation therapy improves survival in patients with brain metastases: report of radiation therapy oncology group phase III study 95–08 (2002) (69)
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525 (2017) (67)
Ultrasound-based image guided radiotherapy for prostate cancer: comparison of cross-modality and intramodality methods for daily localization during external beam radiotherapy. (2006) (66)
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. (2019) (62)
A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023 (2006) (59)
Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. (2005) (57)
The integral biologically effective dose to predict brain stem toxicity of hypofractionated stereotactic radiotherapy. (1998) (54)
Surface applicators for high dose rate brachytherapy in AIDS-related Kaposi's sarcoma. (1997) (50)
Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum. (2004) (49)
Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution (2017) (49)
High dose rate afterloading intracavitary therapy in carcinoma of the cervix. (1991) (47)
Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy. (1997) (45)
Development and impact evaluation of an e-learning radiation oncology module. (2012) (44)
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). (2006) (43)
Prognostic factors for progression in atypical meningioma. (2018) (43)
Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases (2009) (43)
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity‐modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer (2015) (43)
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. (2018) (42)
Volumetric Measurement of Vestibular Schwannoma Tumour Growth Following Partial Resection: Predictors for Recurrence (2012) (42)
An assessment of PTV margin definitions for patients undergoing conformal 3D external beam radiation therapy for prostate cancer based on an analysis of 10,327 pretreatment daily ultrasound localizations. (2007) (41)
Radiosurgery and Accelerated Radiotherapy for Patients with Glioblastoma (1997) (41)
Hypofractionated radiotherapy for favorable risk prostate cancer. (2010) (41)
Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison (2011) (40)
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. (2010) (39)
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. (2014) (39)
Dose distributions in radiosurgery. (1990) (38)
Combined treatment in carcinoma of the nasopharynx (1988) (38)
Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix. (1993) (38)
Big Data Analytics for Prostate Radiotherapy (2016) (38)
Bladder Conservation Treatment in the Elderly Population: Results and Prognostic Factors of Muscle-Invasive Bladder Cancer (2009) (38)
Early toxicity predicts long-term survival in high-grade glioma (2011) (37)
Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers (2010) (37)
Stage III endometrial cancer: preoperative predictability, prognostic factors, and treatment outcome. (2007) (36)
A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524). (2017) (36)
Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era (1996) (35)
Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site. (2017) (35)
High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. (2013) (34)
Communication with the Cancer Patient (1997) (34)
Radiosurgery with photon beams: physical aspects and adequacy of linear accelerators. (1990) (33)
An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02 (2004) (33)
Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. (2010) (33)
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. (2017) (32)
Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. (2009) (32)
Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer (2006) (32)
A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. (2005) (32)
High-dose-rate brachytherapy as the primary treatment of medically inoperable stage I-II endometrial carcinoma. (1995) (31)
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial (2019) (31)
Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): report of RTOG 93-05 protocol (2002) (30)
The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. (2013) (30)
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. (2015) (30)
Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial. (2013) (29)
Efficacy of an Ondansetron Orally Disintegrating Tablet: A Novel Oral Formulation of this 5-HT3 Receptor Antagonist in the Treatment of Fractionated Radiotherapy-Induced Nausea and Emesis (1999) (29)
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database (2018) (28)
Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes. (2013) (28)
Adaptation of wives to prostate cancer following diagnosis and 3 months after treatment: a test of family adaptation theory. (2006) (27)
An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. (2004) (27)
Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. (2004) (26)
Protracted hypofractionated radiotherapy for Graves' ophthalmopathy: a pilot study of clinical and radiologic response. (2012) (26)
Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. (2015) (26)
Increased Pulmonary Toxicity with Bleomycin and Cisplatin Chemotherapy Combinations (1990) (26)
Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA (2016) (26)
Reporting late rectal toxicity in prostate cancer patients treated with curative radiation treatment. (2008) (26)
Sci—Thur AM: YIS ‐ 02: Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy (2014) (25)
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. (2005) (25)
The treatment of stage III carcinoma of the uterine cervix with telecobalt irradiation. (1987) (25)
Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. (2010) (25)
Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions. (2005) (25)
Para-aortic irradiation only appears to be adequate treatment for patients with Stage I seminoma of the testis. (1998) (25)
Local correlation between monte-carlo dose and radiation-induced fibrosis in lung cancer patients. (2008) (24)
Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. (2017) (24)
Tumor Bed Radiosurgery following Resection of Brain Metastases: A Review (2010) (24)
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. (2022) (24)
Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response (2020) (24)
Long-term results of para-aortic irradiation for patients with stage I seminoma of the testis. (2005) (23)
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131 (2015) (23)
Conservative treatment of invasive bladder cancer (2009) (23)
Psychosocial Adjustment of Men During the First Year of Prostate Cancer (2012) (23)
Stereotactic external beam irradiation in previously untreated brain tumors in children and adolescents. (1994) (22)
Short-term Endocrine Therapy Prior to and during Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA ≤ 20: Initial Results of RTOG 94-08 (2010) (22)
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvic for Post-operative Patients with Endometrial Carcinoma (RTOG 0418) (2008) (21)
Stereotactic Radiation in Primary Brain Tumors in Children and Adolescents (1999) (21)
Tolerance of Radiotherapy and Chemotherapy in Elderly Patients With Bladder Cancer (2004) (21)
High Dose Tamoxifen and Radiotherapy in Patients with Glioblastoma Multiforme: A Phase IB Study (2000) (21)
Accelerated fractionation for high‐grade cerebral astrocytomas. Preliminary treatment results (1991) (21)
193 Does the RTOG/EORTC scoring schema (RESS) truly reflect the late radiation morbidity in lung cancer patients? (2005) (21)
Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy (2018) (21)
Dynamic stereotactic radiosurgery in arteriovenous malformation: Preliminary treatment results (1990) (21)
Prostate cancer radiation therapy: A physician's perspective. (2016) (20)
Hypofractionated Stereotactic Radiotherapy for Low Grade Glioma at McGill University: Long-term Follow-up (2006) (20)
Stereotactic radiosurgery in the management of angiographically occult vascular malformations. (2001) (20)
Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer. (2007) (20)
Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. (2012) (20)
Early and late complications following dynamic stereotactic radiosurgery and fractionated stereotactic radiotherapy. (1993) (20)
A halo-ring technique for fractionated stereotactic radiotherapy. (1993) (20)
Radiation Therapy of Testicular Seminoma: A 15‐Year Survey (1992) (19)
Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer (2014) (19)
Clinical experience with a single field rotational total skin electron irradiation technique for cutaneous T-cell lymphoma. (1992) (18)
A technique for fractionated stereotactic radiotherapy in the treatment of intracranial tumors. (1993) (18)
Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer. (2021) (18)
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. (2016) (18)
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. (2020) (17)
Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial. (2014) (17)
Dynamic stereotactic radiosurgery in the palliative treatment of cerebral metastatic tumors (1992) (17)
Stereotactic Radiosurgery in the Management of Intracranial Gliomas (2003) (17)
Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. (2012) (17)
Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤6 brain metastases: a multi-institutional phase II trial (2011) (17)
A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma (1999) (16)
The challenge of scoring radiation-induced lung toxicity. (2009) (16)
A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02). (2008) (16)
Testicular seminoma and Down's syndrome. (2001) (15)
Update of radiation therapy oncology group (RTOG) protocol 9005: Single dose radiosurgical treatment of recurrent brain tumors (1998) (15)
Cone beam CT-based three-dimensional planning in high-dose-rate brachytherapy for cervical cancer. (2010) (15)
Comparison of bat system and a new 3D trans-abdominal ultrasound-based image-guided system for prostate daily localization during external beam radiotherapy (2004) (15)
Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. (1999) (15)
Image-Guided Radiation Therapy Committee (2001) (15)
Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial. (2015) (14)
A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy. (2012) (14)
Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer patients. (2019) (14)
Photon Radiosurgery: A Clinical Review (1992) (14)
Accelerated fractionation in inoperable non‐small cell lung cancer. A phase I/II study (1993) (14)
Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial. (2017) (13)
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution (2015) (13)
Unexpected High Lung Toxicity from Radiation Pneumonitis in a Phase I/II Trial of Concurrent Erlotinib with Limited Field Radiation for Intermediate Prognosis Patients with Stage III or Inoperable Stage IIB Non–small-cell Lung Cancer(NSCLC) (2009) (13)
Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials (2022) (13)
Clinical significance of isolated tumor cells and micrometastasis in low‐grade, stage I endometrial cancer (2018) (13)
Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. (2011) (13)
No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. (2006) (13)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Image-Guided Radiation Therapy Committee. (2001) (13)
Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408 (2017) (13)
Prostate gland edema after single-fraction high-dose rate brachytherapy before external beam radiation therapy. (2010) (13)
Thoracic irradiation in 3weeks for limited-stage small cell lung cancer: Is twice a day fractionation really needed? (2017) (13)
Fractionated dynamic stereotactic radiotherapy for intracranial tumors (1990) (13)
Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. (2006) (13)
The prostate cancer risk stratification project: database construction and risk stratification outcome analysis. (2014) (13)
Flutamide photosensitivity. (1999) (12)
Adjuvant therapy in stage III endometrial cancer confined to the pelvis. (2019) (12)
NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. (2016) (12)
Erythropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma (2004) (12)
Radiation therapy and androgen deprivation in the management of high risk prostate cancer. (2011) (12)
Hematologic Toxicity on RTOG 0418: A Phase II Study of Post-operative IMRT for Gynecologic Cancer (2010) (12)
Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results. (2012) (11)
Physical aspects of the angle-β concept in electron arc therapy (1991) (11)
Efficacy and Safety of IMRT after Surgery in Patients with Endometrial Cancer: RTOG 0418 Phase II Study (2011) (10)
Detrimental effect of neoadjuvant chemotherapy in patients with stage-iiib carcinoma of the cervix - results of a randomized trial. (1992) (10)
Elevated serum cytokines in patients with malignancy and weight-loss. (1993) (10)
Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. (2011) (10)
Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas (2008) (10)
Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer (2007) (10)
Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. (2017) (10)
The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer. (2014) (10)
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. (2022) (10)
Killing Two Birds with One Stone: A Dosimetric Study of Dual Target Radiosurgery Using a Single Isocenter (2006) (10)
Communication with the cancer patient. Information and truth in Brazil. (1997) (9)
Postoperative radiation therapy after hip replacement in high-risk patients for development of heterotopic bone formation. (2011) (9)
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). (2022) (9)
Small cell carcinoma of the endometrium: report of a case and review of the literature. (2009) (9)
Clinical experience with electron pseudoarc therapy. (1993) (9)
Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. (2014) (9)
Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer (2015) (9)
Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer (2017) (8)
OPTIMIZING TREATMENT IN INTERMEDIATE RISK PROSTATE CANCER: SECONDARY ANALYSIS OF A RANDOMIZED PHASE III TRIAL. (2021) (8)
Genetic landscape of extreme responders with anaplastic oligodendroglioma (2017) (8)
Fractionated stereotactic radiotherapy for intracranial neoplasms. (1992) (8)
Quality assurance in radiation therapy: clinical aspects. (1984) (8)
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402. (2009) (8)
Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. (2011) (7)
Is There a Detrimental Effect of Waiting for Radiotherapy for Patients With Localized Prostate Cancer? (2006) (7)
Searching for optimal dose-volume constraints to reduce rectal toxicity after hypofractionated radiotherapy for prostate cancer. (2010) (7)
Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. (2011) (7)
Cylindrical dose distributions in pseudodynamic rotation radiosurgery: an experimental study. (1993) (7)
Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical cancer patients with stage IIIB disease and bilateral parametrial involvement: a phase I-II study. (2003) (7)
Single fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer: Long-term results. (2011) (7)
Reply to L. Collette et al and C.M. Tangen et al (2009) (7)
Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521. (2020) (7)
Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer (2020) (7)
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. (2016) (6)
Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials (2018) (6)
Is Post‐Operative Intracavitary Therapy a Necessary Component of Treatment for Carcinoma of the Endometrium? (1991) (6)
Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. (2019) (6)
The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials (2018) (6)
Dosimetry of hip irradiation for the prevention of heterotopic bone formation after arthroplasty. (1999) (6)
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors (2022) (6)
Primary malignant mesodermal ovarian sarcomas (2004) (6)
Prostate cancer radiotherapy 2002: the way forward. (2005) (6)
Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy. (2019) (6)
A phase II trial of mitomycin, ifosfamide and cisplatin in recurrent carcinoma of the cervix. (2000) (5)
A Phase 2 Study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with Concomitant and Adjuvant Metformin and Temozolomide (TMZ) in Patients with Glioblastoma (2020) (5)
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. (2019) (5)
Short-course irradiation as adjuvant treatment of surgically resected single brain metastases. (2009) (5)
Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial. (2021) (5)
The impact of the duration of adjuvant hormonal therapy in patients with unfavorable prognosis prostate cancer treated with radiotherapy: Secondary analysis of RTOG 85–31 (2007) (5)
A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab (Bev) Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer: One-Year Results from RTOG 0921 (2013) (5)
Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes. (2015) (5)
Accelerated Fractionation for High-Grade Cerebral Astrocyfomas (1991) (5)
Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary? (2020) (5)
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials (2022) (5)
Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126 (2022) (4)
Phase II trial with carboplatin/gemcitabine induction chemotherapy followed by radiotherapy concomitantly with paclitaxel/gemcitabine in stage III non-small cell lung cancer (NSCLC). (2006) (4)
Rectal Planning Risk Volume Correlation with Acute and Late Toxicity in 3-Dimensional Conformal Radiation Therapy for Prostate Cancer (2011) (4)
Abstract 736: RTOG 0320:A phase III trial comparing whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone versus WBRT with temozolomide (TMZ) or erlotinib for non-small cell lung cancer (NSCLC) and 1-3 brain metastases (2012) (4)
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. (2012) (4)
A dosimetric comparison of two high-dose-rate brachytherapy planning systems in cervix cancer: standardized template planning vs. computerized treatment planning. (2008) (4)
Long-Term Update of NRG Oncology RTOG 94-08 (2018) (4)
Assembling the brain trust: the multidisciplinary imperative in neuro-oncology (2019) (4)
Acute and Late Urinary Toxicity After Radiation Therapy in Men With and Without an Intact Prostate Gland: A Secondary Analysis of RTOG 9408 and 9601 Suggesting This Toxicity is Not Due to Bladder Injury (2012) (4)
Radiation Therapy With or Without Short-Term Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer: Results of a Phase 3 Trial (2016) (4)
Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience. (2015) (4)
A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy. (2015) (4)
Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. (2020) (4)
81 The role of MRI fusion in radiotherapy planning of pediatric CNS tumors (1999) (4)
High-Grade Gliomas (2008) (3)
Comparison between Cone Beam CT Based Three-dimensional Planning and Modified Monte Carlo Dose Calculations in Intracavitary Brachytherapy for Cervical Cancer (2009) (3)
Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes. (2016) (3)
Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer (2014) (3)
The use of hypofractionated accelerated intensity modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a phase I trial (2001) (3)
Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233. (2014) (3)
Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized phase III trial (2002) (3)
Is Post-Treatment FDG-PET/CT Useful in Differentiating Tumor From Fibrosis After Curative Radiotherapy (RT) Alone for Lung Cancer? (2007) (3)
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort (2021) (3)
Radiation-induced endothelin production by human endothelial cells in vitro (1992) (3)
Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer. (1994) (3)
Prospective phase I study on testicular castration induced by radiation treatment. (2015) (3)
The Prostate Cancer Risk Stratification (ProCaRS) Project: Database Construction and Outcome Analysis (2012) (2)
Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial (2017) (2)
"Long-term results of moderate hypofractionation to prostate and pelvic nodes plus androgen suppression in high-risk prostate cancer." (2020) (2)
Radiosurgery of cerebral ateriovenous malformations with the dynamic stereoactic irraddiation (1989) (2)
A role for magnetic susceptibility in synthetic computed tomography. (2021) (2)
Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention (2020) (2)
Analysis of Structural Changes in Hippocampal and Amygdala Volume After Systemic Therapy and Prophylactic Cranial Irradiation in Patients With Limited Stage-Small Cell Lung Cancer (2013) (2)
Physical aspects of the angle-beta concept in electron arc therapy. (1991) (2)
30 An assessment of inter-fraction prostate motion based on 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy (EBRT) (2006) (2)
Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31. (2019) (2)
Examination of the Dose-Effect Relationship of Radiation-Induced Hypopituitarism: Results of a Case-Control Study (2021) (2)
In reply to Dr. Kondziolka et al (2005) (2)
The use of Cone Beam CT-based Three-dimensional Planning in Intracavitary Brachytherapy for Cervical Cancer (2008) (2)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gynecology Cancer Working Group. (2001) (2)
Chemosensitized radiosurgery for recurrent brain metastases (2012) (2)
MP61-08 A PHASE I/II TRIAL OF TRANSURETHRAL SURGERY FOLLOWED BY A COMBINATION OF ATEZOLIZUMAB AN ANTI-PDL-1 (MPDL3280A) WITH TRIMODAL THERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (2020) (2)
P-207 Phase II trial with carboplatin/gemcitabine (Cb/G) induction chemotherapy (CT) followed by radiotherapy concomitantly with paclitaxel/gemcitabine (P/G) in Stage III non small cell lung cancer (NSCLC) (2005) (2)
Impact of Adjuvant Hormonal Therapy Duration and Timing of Salvage Hormonal Therapy in Prostate Cancer Patients With Unfavorable Prognosis Treated by Radiotherapy. A Secondary Analysis of RTOG 8531 (2007) (2)
Gynecology Cancer Working Group (2001) (2)
[Prostate and seminal vesicle displacement following urethrography: a computed tomography-based study]. (2005) (2)
724 TESTOSTERONE RECOVERY IN PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH 36 VS 18 MONTHS OF ANDROGEN BLOCKADE AND PELVIC IRRADIATION (2011) (2)
Evaluation and visualization of radiogenomic modeling frameworks for the prediction of normal tissue toxicities (2015) (2)
Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials (2017) (2)
69 Preliminary results with hypofractionated radiation therapy (HRT) alone as the curative treatment for patients with early stage, medically inoperable non-small cell lung cancer (NSCLC) (2005) (2)
Hypofractionated Intensity Modulated Radiation Therapy to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer (2018) (2)
A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis (2018) (2)
ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402 (2019) (2)
CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570). (2022) (2)
Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy (2021) (2)
Hipofracionamento no câncer de próstata Hypofractionated radiotherapy in the management of prostatic cancer (2004) (2)
A Canadian Response to the Coronavirus Disease 2019 (COVID-19) Pandemic: Is There a Silver Lining for Radiation Oncology Patients? (2020) (2)
Analysis of Prognostic Factors for Local Recurrence in Atypical Meningiomas (2016) (2)
B5-02: Radiotherapy volume delineation with PET in lung cancer may be less useful than foreseen (2007) (1)
GENO-21BRCA1 PROTEIN EXPRESSION PREDICTS SURVIVAL IN GLIOBLASTOMA PATIENTS FROM A NRG ONCOLOGY/RTOG COHORT (2015) (1)
Trial Sponsorship and Self-Reported Conflicts of Interest in Clinical Trials of Central Nervous System Malignancies (2016) (1)
Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials. (2010) (1)
Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126. (2022) (1)
1110 : Motexafin Gadolinium-Based Treatment Planning MRI Identifies Occult Brain Metastases Amenable to Stereotactic Radiosurgery: Imaging Results of a Phase II Trial of Motexafin Gadolinium and Whole Brain Radiotherapy With Stereotactic Radiosurgery (2006) (1)
Acute Toxicity in High-Risk Prostate Cancer Patients Treated with Hypofractionated IMRT with Simultaneous Integrated Boost (2012) (1)
Comparison of LDR Brachytherapy Versus External Beam Radiation Therapy for Low- And Intermediate-Risk Prostate Cancer: A Propensity-Score Matched Analysis (2014) (1)
36 Late rectal toxicity after hypofractionated radiation therapy (RT) for prostate cancer: Lack of correlation with recognized dose-volume guidelines (2006) (1)
PO-0668 TESTOSTERONE VARIATION IN INTERMEDIATE RISK PROSTATE CANCER TREATED WITH ANDROGEN BLOCKADE AND RADIOTHERAPY (2012) (1)
USE OF FDG-PET / TC SCAN IN THE PLANNING OF RADIATION THERAPY FOR NON-SMALL CELL LUNG CANCER * (2007) (1)
Paradigms in Tumor Bed Radiosurgery Following Resection of Brain Metastases (2012) (1)
Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium (2001) (1)
Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. (2013) (1)
In Reply to Dr. Scarbrough et al. (2007) (1)
Volumetric Growth Measurements of Pituitary Macroadenomas Following Surgical Resection and Indications for Early Adjuvant Radiation Therapy (2014) (1)
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126 (2022) (1)
Improved local control with RSR-13 and concurrent radiation therapy in a phase II study for locally advanced inoperable non-small cell lung cancer (2001) (1)
Serum Testosterone Changes in Patients Treated With Radiation Therapy Alone for Prostate Cancer on RTOG 9408 (2013) (1)
Predictors of survival for patients with brain metastases: results of a randomized phase III trial (2002) (1)
Inferior Clinical Outcomes for Patients With Positive Post-Radiation Therapy Prostate Biopsy: Results From Prospective Randomized Trial RTOG 94-08 (2013) (1)
Biochemical failure as single abnormality in patients with prostate cancer following radical treatment with external radiotherapy: follow-up without immediate treatment. (2004) (1)
Can high-dose-rate brachytherapy be an alternative to surgery in selected patients with stage I endometrial carcinoma (2004) (1)
Radiation therapy (RT) alone vs intensive procarbazine-CCNU-vincristine (I-PCV) chemotherapy followed by radiation therapy for anaplastic oligodendroglioma (AO) and mixed oligo-astrocytoma (MOA): Results of radiation therapy oncology group (RTOG) - intergroup protocol 94–02 (2004) (1)
1080 Induction chemotherapy followed by concurrent RSR13 (Efaproxiral) and trt for patients with locally advanced NSCLC: mature results of a phase II study and comparison with the results from RTOG 94-10 (2003) (1)
Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial. (2017) (1)
HYPOFRACTIONATED EXTERNAL BEAM RADIATION THERAPY AND SINGLE FRACTION HDR-BRACHYTHERAPY: IMPROVING THE RESULTS IN THE TREATMENT OF INTERMEDIATE-RISK PROSTATE CANCER (2008) (1)
122 A phase-II Trial of intermittent androgen ablation in patients presenting biochemical failure after definitive radiotherapy for localized prostate cancer (2005) (1)
Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis. (2022) (1)
Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer (2018) (1)
Stereotactic Radiosurgery and Radiotherapy in the Management of High-Grade Gliomas (2015) (1)
The Calculation of an Integral Biologically Effective Dose in Fractionated Stereotactic Radiotherapy (1996) (1)
Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial (2020) (1)
The Initial Report of RTOG 0524: Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer (2014) (1)
Pelvic Lymph Nodes Displacement in High-Risk Prostate Cancer Patients Treated With Image-Guided IMRT With 2 Independent Target Volumes (2014) (1)
BRCA1 Protein Expression Predicts Survival in Glioblastoma Multiforme (GBM) Patients From a RTOG Cohort (2015) (1)
Causes of death in intermediate- and high-risk prostate cancer treated with radiotherapy with or without androgen deprivation therapy: Analysis from two phase III trials. (2016) (1)
Reply to S.G. Williams et al (2009) (1)
Subject Index Vol. 59, 1992 (1992) (1)
Long term results of high dose rate brachytherapy in cervix cancer using small number of fraction (2000) (1)
Bowel and Bladder Function of Men on a Phase 3 Randomized Study of High Versus Standard Dose of 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (2015) (1)
Phase II trial with carboplatin/gemcitabine (Cb/G) induction chemotherapy (CT) followed by radiotherapy concomitantly with paclitaxel/gemcitabine (P/G) in stage III non small cell lung cancer (NSCLC): Preliminary report (2005) (1)
Radiation Therapy Oncology Group (RTOG) 9408: A Secondary Analysis of the Risk of Death From Second Cancers Comparing Whole Pelvic (WP) Radiation Therapy (RT) to Prostate Only (PO) RT and Neoadjuvant Hormonal Therapy (NHT) + RT to RT Alone (2013) (1)
Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study (2020) (1)
Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. (2021) (1)
Intermediate Risk Prostate Cancer Treated with Hypofractionated External Beam Radiotherapy without Androgen Deprivation: Preliminary Results and Toxicity Analysis (2010) (1)
Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials (2023) (0)
Po‐Poster ‐ 03: A comparison of intensity‐modulated radiotherapy versus 3D conformal radiotherapy for prostate cancer patients whose rectal reaction to prior conventional radiotherapy was known (2005) (0)
Phase II Trial with Carboplatin/Gemcitabine (Cb/G) Induction Chemotherapy (CT) Followed by Radiotherapy Concomitantly with Paclitaxel/Gemcitabine (P/G) in Stage III Non-Small Cell Lung Cancer (NSCLC) (2005) (0)
24 Subsequent Androgen Deprivation Therapy After Initial Treatment in Intermediate Risk Prostate Cancer: Prospective Data from a Phase III Trial (2019) (0)
172 Pre- and post-treatment PET/CT to evaluate the response of non-small cell lung cancer (NSCLC) treated with curative radiotherapy alone (RT) (2006) (0)
Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with motexafin gadolinium (2001) (0)
The use of stereotactic radiosurgery in the treatment of intracerebral cavernous angioma (1998) (0)
34 SINGLE FRACTION HIGH DOSE RATE BRACHYTHERAPY AND HYPOFRACTIONATED EXTERNAL BEAM RADIATION THERAPY IN THE TREATMENT OF LOCALIZED PROSTATE CANCER (2009) (0)
21 The impact of FDG-PET on radiation therapy gross tumour volume (GTV) delineation in non-small cell lung cancer (NSCLC) may be smaller than predicted (2006) (0)
Central Nervous System Tumors (2015) (0)
PD57-12 ROLE OF ROUTINE BIOPSY AFTER RADIATION-BASED THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER (2019) (0)
Local failure, distant metastasis, and survival after definitive radiotherapy for intermediate- and high-risk prostate cancer: An individual patient-level meta-analysis of 18 randomized trials. (2022) (0)
Editorial: The Role of Modern Neuro-oncology in the Treatment of Primary CNS Tumors, and Brain and Spinal Metastases (2020) (0)
Differential Regional Brain Atrophy Following Prophylactic Cranial Irradiation in Small Cell Lung Cancer Patients (2008) (0)
SU-FF-J-26: Analysis of 10,327 Pre-Treatment Ultrasound Localizations for 387 Prostate Cancer Patients Treated with Conformal 3D External Beam Radiation Therapy (2006) (0)
The impact of varying rectal contours on rectal dose in prostate cancer patients treated with hypofractionated radiation (2007) (0)
Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials (2019) (0)
Reply to K. Lin et al (2010) (0)
Quality assurance in radiation therapy: clinical aspects. [Latin America] (1984) (0)
Causes of death in localised prostate cancer: Long term data from two phase III trials (2018) (0)
000392 STAGE III ENDOMETRIAL CANCER - PREOPERATIVE PREDICTORS OF EXTRAUTERINE SPREAD AND INFLUENCE OF ADJUVANT THERAPY ON SURVIVAL (2005) (0)
Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial (2017) (0)
Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer (2022) (0)
Survival a nd N eurologic O utcomes i n a R andomized T rial o f Motexafin G adolinium a nd W hole-Brain R adiation T herapy i n Brain M etastases (2003) (0)
Post-renal acute renal failure during pelvis irradiation for prostate cancer. (2002) (0)
Outcomes of Adjuvant Therapy in Stage 3 Endometrial Cancer Confined to the Pelvis (2016) (0)
O-124 Survival comparison between RTOG 94-10 and a phase 2 study of induction chemotherapy followed by concurrent RSR13 (Efaproxiral) and TRT in patients with locally advanced NSCLC (2003) (0)
56: Phase 2 Trial of Neoadjuvant Metformin and Temozolomide Followed by Hypofractionated Accelerated Radiotherapy with Concomitant and Adjuvant Metformin and Temozolomide in Patients with Newly Diagnosed Glioblastom (2022) (0)
53: Acute and Late Toxicity in High-Risk Prostate Cancer Patients Treated with Androgen Suppression and Hypofractionated Radiotherapy (Hyport) to the Prostate and Pelvic Nodes (2016) (0)
219 Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer confined to the pelvis (2005) (0)
Ultrasound for radiotherapy targeting. Authors' reply (2007) (0)
32 HYPOFRACTIONATED RADIATION THERAPY (RT) FOR LOCALIZED PROSTATE CANCER (PC) (2009) (0)
1083 A completed phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine followed by accelerated thoracic irradiation, (TRT) in inoperable NSCLC (1995) (0)
SP-0011 Unified Radiogenomic Prediction of Late Radiotherapy Toxicities (2019) (0)
ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525 (2015) (0)
1096 What to do with asymptomatic prostate cancer patients with rising PSA after curative treatment with external beam radiotherapy (RT) (2003) (0)
Can combined chemo-radiation be started after induction chemotherapy in the curative treatment of stage III non-small cell lung carcinoma (NSCLC)? A multicenter, phase II study 5-year update. (2011) (0)
132 A Comparison of individualized treatment planning (ITP) to a standardized template planning (STP) approach in high dose rate brachytherapy (H DRB) for cervix cancer (Cxca) (2006) (0)
Poster ViewingAnisotropic Bladder Planning Target Volume is Adequate When Using Cone Beam Computed Tomography as a Form of Image Guided Radiation Therapy (2017) (0)
Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy (2022) (0)
145 Initial results of RTOG 95-06: A phase I/II trial of transurethral surgery and fractionated twice-daily radiation with concurrent cisplatin and 5-fluorouracil followed either by selective bladder preservation or cystectomy for patients with muscle-invading bladder cancer (1999) (0)
Abstract 609: The predictive power of tertiary lymphoid structures in assessing response to trimodal therapy in muscle invasive bladder cancer (2023) (0)
[Brain metastasis. Palliative treatment with radiosurgery]. (1995) (0)
OC-0057: Randomized phase 2 trial of radiation with either gemcitabine or 5FU/cisplatin in bladder cancer (2018) (0)
36 Conformal endorectal high dose rate brachytherapy treatment of locally advanced and resectable rectal carcinoma using 3D treatment planning (2001) (0)
Biochemical recurrence (BCR) surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate (BCRSCRAP): A meta-analysis from MARCAP Consortium. (2023) (0)
Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer (2016) (0)
Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. (2022) (0)
148 POST OPERATIVE RADIATION THERAPY (RT) AFTER HIP REPLACEMENT IN HIGH RISK PATIENTS FOR DEVELOPMENT OF HETEROTOPIC BONE FORMATION (HBF) (2009) (0)
Improving the Therapeutic Ratio in the Treatment of Intermediate Risk Prostate Cancer With Single Fraction High Dose Rate Brachytherapy and Hypofractionated External Beam Radiation Therapy (2007) (0)
34 Comparison of Planning Methods for the Treatment of Acoustic Neuromas with Linear Accelerator-Based Stereotactic Radiotherapy (2005) (0)
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. (2023) (0)
2512 : Correlation of Radiation-Induced Fibrosis and Local Dose-Related Parameters in Conformal Non-Small Cell Lung Cancer Radiation Therapy (2006) (0)
Outcomes Based on Risk Factors in Intermediate Risk Prostate Cancer: a Secondary Analysis of a Randomized Phase III Trial (2019) (0)
Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126. (2021) (0)
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution (2015) (0)
Results of a Phase 2 Clinical Trial of Neo-Adjuvant Temozolomide (TMZ), Followed by Concurrent TMZ and Hypofractionated Accelerated External Beam Radiation Therapy (Ac-EBRT) With Limited Margins, and Adjuvant TMZ for Patients With Glioblastoma Multiforme (GBM) (2013) (0)
Radiation Therapy-Induced Castration in Men With Advanced Prostate Cancer: Results of a Prospective Phase 1 Study (2014) (0)
The rate of prostatic involvement in men treated with radical cystectomy for muscle invasive bladder cancer. (2022) (0)
Hypofractionated radiation therapy for glioblastoma (2017) (0)
Optimal Duration of Androgen Deprivation Therapy (ADT) with Definitive Radiotherapy for Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis from the International MARCAP Consortium (2022) (0)
PV-0502: Post-operative radiation therapy in atypical meningiomas: analysis of prognostic factors (2017) (0)
167 Is 5-year survival rate a real measure of outcome in cervix cancer patients treated by radiotherapy? Long-term results in patients treated with external beam radiation therapy and high dose rate brachytherapy (2003) (0)
483 Erythropoietin receptor expression and the in-vitro effect of erythropoietin on the radiation-response of different cancer cell lines (2003) (0)
Development of an Interactive, Web-based, Radiological Anatomy Learning Module for Radiation Oncology Residents: A Pilot (2005) (0)
A Dosimetric Analysis of IMRT versus 3D Conventional Radiation in Vulvar Cancer (2008) (0)
On the selection of optimization parameters for an inverse treatment planning replacement of a forward planning technique for prostate cancer (2002) (0)
BI-12RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS (2014) (0)
2080 Can we omit ipsilateral pelvic irradiation in patients with stage I seminoma of the testis (1996) (0)
62: Acute Toxicity in High-Risk Prostate Cancer Patients Treated with Extreme Hypofractionation (HRPC-SBRT) (2022) (0)
A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients with an Unmethylated MGMT Gene Promoter (2022) (0)
Hypofractionated IMRT With Simultaneous Integrated Boost for High-risk Prostate Cancer Patients: Acute Toxicity Report (2012) (0)
Abstracts of the 6th Canadian Neuro-Oncology Meeting May 18–21, 1994 Lake Louise, Alberta (1994) (0)
CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data (2023) (0)
218 Development of an interactive, web-based, radiological anatomy learning module for radiation oncology residents: A pilot (2005) (0)
WE-D-BRE-02: BEST IN PHYSICS (THERAPY) - Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy. (2014) (0)
42 A novel approach using accelerated hypo-fractionation-IMRT (AH-IMRT) and temozolomide (TMZ) in patients with glioblastoma multiforme (GBM) (2006) (0)
Choosing Wisely in Low Grade, Low Risk Endometrial Cancer Patients: the Value of Pre-Operative MRI, Lymph Node Dissection, and Postoperative Detailed Pathology (2018) (0)
A phase III trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated concomitant boost irradiation in inoperable non-small cell lung cancer☆ (1998) (0)
30 Retrospective Evaluation of the Effects of Interobserver Contouring Practices in Clinical Practice (2019) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
Post–Biochemical Failure Risk Stratification to Predict Survival in Prostate Cancer: A Recursive Partitioning Analysis (2015) (0)
Is Postoperative Radiotherapy Needed in the Management of Adult Craniopharyngiomas? (2021) (0)
Second Malignancies as First Cause of Death in Localized Prostate Cancer Treated With Radiation Therapy: Data from Two Phase 3 Trials (2016) (0)
Efficacy of Bicalutamide Monotherapy in Prostate Cancer: A Network Meta-Analysis of 10 Randomized Trials (2022) (0)
RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825 (2015) (0)
Copy Number Variations as Predictors of Late Toxicities in Prostate Cancer (2013) (0)
1115: Age as an Independent Prognostic Factor in Patients With Glioblastoma: A Radiation Therapy Oncology Group Analysis (2006) (0)
Reply from Dr. Luis Souhami (2010) (0)
BENEFICIAL OUTCOMES AFTER PCV PLUS RT IN OLIGODENDROGLIAL TUMORS ARE ASSOCIATED WITH DETECTION OR RISK OF AN IDH MUTATION. (2014) (0)
Combined Risk Factors and Outcomes in High-Risk Prostate Cancer: Secondary Analysis of a Phase III Trial (2022) (0)
Volumetric Measurement of Acoustic Neuroma Tumor Growth Following Resection and Predictors for Recurrence (2011) (0)
55: The Rate of Prostatic Involvement in Men Treated with Radical Cystectomy for Muscle Invasive Bladder Cancer (2020) (0)
Prostate Bed Radiotherapy Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy Is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial (2019) (0)
Nadir Prostate-Specific Antigen After Neoadjuvant Androgen Suppression (AS) in Prostate Cancer Patients Receiving Short-term AS and Radiation Therapy: Pooled Analysis of Four NRG Oncology/RTOG Randomized Clinical Trials (2015) (0)
Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes. (2013) (0)
A Comparison of Helical Tomotherapy (HT), Fixed-field Intensity-modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3DCRT) Plans in Stereotactic Radiation Therapy of Skull Base Meningioma (2008) (0)
SU-GG-J-23: Accurate Dose Assessment for Prostate Cancer Patients Using 3D Ultrasound and Monte Carlo Dose Calculation (2008) (0)
In Reply to Khalifa and Sargos. (2021) (0)
Data Driven Radiogenomic Modeling of Radiation Induced Toxicities in Prostate Cancer (2015) (0)
Radiation Therapy in the Management of Lung Cancer (2011) (0)
Growth of Pituitary Macroadenomas Postpartial Resection: Implications for Adjuvant Radiotherapy (2018) (0)
Temozolomide in combination with stereotactic radiosurgery for recurrent brain metastases: A phase I study. (2010) (0)
Long-term Analysis of Pure Low Grade Oligodendroglioma (2008) (0)
Testosterone Suppression in Patients with Intermediate Risk Prostate Cancer Treated with External Beam Radiotherapy Alone (2011) (0)
Hypofractionation IMRT in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer (2013) (0)
B5-03: Dose-effect correlation for radiotherapy induced fibrosis using Monte Carlo dose calculations and a novel fibrosis image segmentation technique. (2007) (0)
171 High-Dose-Rate Brachytherapy as Monotherapy for the Treatment of Intermediate Risk Prostate Cancer: Toxicity Results (2019) (0)
Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy. (2017) (0)
Reply from Drs. Luis Souhami and Fabio Cury (2010) (0)
In response to Drs. Vordermark and Kölbl (2005) (0)
Hypofractionated external beam radiotherapy and single fraction HDR brachytherapy: Improving the results in the treatment of intermediate-risk prostate cancer (2008) (0)
A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (Trial ****) (2017) (0)
Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402. (2016) (0)
000172 ENDOMETRIAL CANCERS IN WOMEN UNDER 40 YEARS: INSIGHTS FROM THE MCGILL EXPERIENCE (2005) (0)
49: Comparison of 5-Year Survival Between RTOG-94-10 and a Phase 2 Study of Induction Chemotherapy Followed by Efaproxiral + Radiotherapy in Patients With Locally Advanced NSCLC (2006) (0)
Intermediate-Risk Prostate Cancer Treated With Hypofractionated External Beam Radiation Therapy Alone: Long-term Outcomes (2015) (0)
19 Integrating PET-CT scans and radiation treatment planning of non-small cell lung cancer (2006) (0)
Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial. (2023) (0)
P-715 Hypofractionated radiation therapy (HRT) alone as the curative treatment for patients with early stage, medically inoperable non-small cell lung cancer (NSCLC) (2005) (0)
Conformal high dose rate endorectal brachytherapy: a promising alternative downstaging modality for patients with resectable rectal cancer (2001) (0)
Predictors of Outcome and Patterns of Failure in Patients with Pathologic Stage III Endometrial Cancer Confined to the Pelvis (2005) (0)
2342 : A Dosimetric Comparison of Two High-Dose-Rate Brachytherapy Planning Systems in Cervix Cancer: Individualized Treatment Planning Versus Standardized Template Planning (2006) (0)
Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: Long-term data from two randomized trials. (2023) (0)
Guideline for testosterone recovery in localized prostate cancer treated with different ADT duration: Long-term data from two prospective randomized trials (2020) (0)
Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial. (2018) (0)
Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy (2014) (0)
80 Linear registration as a tool for the evaluation of post radiotherapy complications in lung cancer (2005) (0)
151 Volumetric changes post single fraction high-dose rate brachytherapy (HDRB) as a boost to external beam radiation therapy (EBRT) in prostate cancer (PCa) - should it be considered an important factor for margin definition? (2006) (0)
Prognostic Factors of Survival for Anaplastic Gliomas (2014) (0)
11 Prostate Bed Treatment Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial (2019) (0)
Correlation Between PSA Bounce, Time to Nadir, and Biochemical Failure in Patients With Prostate Cancer Treated With a Combination of HDR-Brachytherapy and Hypofractionated External Beam Radiation Therapy (2012) (0)
155: Calcification and Image Guided Radiotherapy for Localized High-Risk Prostate Cancer (2022) (0)
192 Ten years experience with small cell lung cancer (SCLC) — limited stage (LS) at the McGill University Health Centre (2005) (0)
Effect Of Hormone Therapy Within Risk Groups Defined By Generalized Competing Event Model: Ancillary Analysis Of NRG Oncology’s RTOG 9408 (2020) (0)
Acute Neurological Toxicity (NT) and Long-Term Outcomes in High-grade Glioma RTOG Trials (2010) (0)
MP41-14 IMPACT OF PD-L1 EXPRESSION IN THE TUMOR MICROENVIRONMENT ON ONCOLOGICAL OUTCOMES FOR PATIENTS TREATED WITH TRIMODALITY THERAPY FOR MUSCLE INVASIVE BLADDER CANCER: A POTENTIAL BIOMARKER FOR PATIENT SELECTION? (2021) (0)
98: Impact of PD-L1 Expression on Oncological Outcomes for Patients Treated with Trimodality Therapy for Muscle Invasive Bladder Cancer (2021) (0)
59 Second primary tumors in prostate cancer: Data from two phase III trials (2016) (0)
318Radiosurgery for brain metastases: Pattern of failure (1996) (0)
802: Predictors of Progression on Repeat Prostatic Biopsies in Patients with Localized Prostate Cancer on Surveillance (2004) (0)
Small Cell Lung Cancer Limited Disease (LSCLC): Are Long Treatments With Higher Doses Really Needed? (2015) (0)
Prophylactic Cranial Irradiation in Patients With Limited Stage Small Cell Lung Cancer: A Pilot Study Investigating the Effects of Radiation Therapy on Neurocognitive Function (2012) (0)
1029 A phase II trial of the radiosensitizer: Etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG PROTOCOL #95-02) (1999) (0)
PO-0694 PROSTATE ULTRASOUND-BASED IGRT. CAN THE PROSTATE BE DISPLACED BY THE ULTRASOUND PROBE PRESSURE? (2012) (0)
Hypofractionated, Reduced Margin, Intensity Modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Patients with Glioblastoma Multiforme: A Pattern of Failure Analysis (2011) (0)
Hypofractionated Versus Conventionally Fractionated Radiation Therapy for Prostate Cancer: Five-Year Oncologic Outcomes of the Dutch Randomized Phase 3 HYPRO Trial (2015) (0)
4021 POSTER Testosterone recovery following prolonged adjuvant androgen blockade in localized prostate cancer: is there an effect on outcome? (2007) (0)
181 ULTRASOUND IMAGE GUIDED RADIOTHERAPY (RT): POSTERIOR DISPLACEMENT OF THE PROSTATE (PST) INDUCED BY THE ULTRASOUND (US) PROBE IN PATIENTS WITH A DISTENDED RECTUM (2009) (0)
In-vitro effect of erythropoietin on the radiosensitivity of Hela and U87 cell lines (2002) (0)
TH-E-ValB-02: Image Registration-Based Tool for Correlation Studies of Radiation-Induced Fibrosis and Local Dose-Related Parameters in Conformal Non-Small Cell Lung Cancer Radiation Therapy (2006) (0)
4040 POSTER Salvage 3-D conformal radiation therapy for patients developing biochemical failure post prostatectomy: a single institution experience (2007) (0)
Poster: Physics track: Radiobiological planning, predictive models of outcome including NTCP/TCP modellingPO-0901: Evaluation of NTCP radiogenomic modelling frameworks in hypofractionated prostate cancer patients (2015) (0)
Funding Source, Self-Reported Conflicts of Interest, and the Interpretation of Conclusions of Phase 1, 2, and 3 Trials in Neuro-Oncology (2016) (0)
Endometrial Carcinoma in Elderly Women: Disease Outcome and Treatment Morbidity (2007) (0)
Comparison of Two Phase II Trials of Neoadjuvant Temozolomide Followed with Concomitant and Adjuvant Temozolomide and Hypofractionated Accelerated Radiotherapy with or without Metformin in Patients with Newly Diagnosed Glioblastoma (2022) (0)
The treatment of medically inoperable endometrial cancer with high dose-rate brachytherapy (1994) (0)
“Tri-modality” Therapy for Large Brain Metastases (2012) (0)
109: Prostate Cancer-Specific Death Rates in Localized Prostate Cancer: Data from Two Randomized Trials (2022) (0)
Outcomes Comparison Using PSA Cut-Off Values Of 0.1 Or 0.2 Ng/Ml At 6 Months In Localized High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy And Radiotherapy: Prospective Data From A Phase III Trial (2020) (0)
Malignant lymphoma of the thyroid gland. [/sup 60/Co] (1980) (0)
NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402 (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luis Souhami?

Luis Souhami is affiliated with the following schools:

McGill University

Luis Souhami's Academic­Influence.com Rankings

Luis Souhami's Degrees

Why Is Luis Souhami Influential?

Luis Souhami's Published Works

Published Works

What Schools Are Affiliated With Luis Souhami?

Luis Souhami's AcademicInfluence.com Rankings